Biotechnology

MRI of knee
Biotech

Unity Biotechnology, with big hopes for longevity drugs, shows results highlighting long road ahead

By Matthew Herper

San Francisco panel - still
Play
Biotech

Watch: From CRISPR to machine learning, how tech is reinventing how medicines are made

By STAT staff

Biotech

Pfizer spends $11.4 billion to buy Array BioPharma for its cancer drug chemistry

By Matthew Herper

Glaxo Smith Kline
Biotech

CRISPR lab begs the question: Where is the line between industry and academia?

By Matthew Herper

San Francisco panel - still
Biotech

Architects of a new CRISPR partnership defend academic-industry research model

By Rebecca Robbins

Biotech

Bluebird’s gene therapy for a rare blood disease will cost $1.8 million. Cue the pricing debate

By Adam Feuerstein

Josiah Zayner
Biotech

‘It felt like an ’80s criminal drama’: What happened when a biohacker met bureaucrats investigating him

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

sickle cell disease blood sample
Biotech

Global Blood’s sickle cell disease drug heads to the FDA, but questions about patient benefit still linger

By Adam Feuerstein

Play
The Readout LOUD

Listen: Biohacking meets bureaucracy, and the latest twist in CRISPR world

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

Fecal transplant lab
Biotech

FDA warns of one patient death from a fecal transplant

By Kate Sheridan

Jennifer Doudna - Genome Editing Conference
Exclusive

GSK partners with CRISPR pioneer Doudna to search for new drugs

By Matthew Herper

STAT SPOTLIGHT
Biotech

Startup Spotlight: Akrevia Therapeutics eyes safer immunotherapies

By Kate Sheridan

Senator Chuck Grassley
Politics

Senators want to know if HHS money went to Chinese genomics firms

By Damian Garde

X-ray
Biotech

Next up for KRAS-blocking cancer drug fans: a hugely important data reveal from Mirati Therapeutics

By Adam Feuerstein

Knee Xray
Biotech

Fast-growing Vericel finds success on two fronts: knee surgery and burn care

By Jonathan Saltzman — Boston Globe

colored DNA sequencing
Biotech

Startup offering free DNA sequencing signs first pharma sponsor

By Sharon Begley

Light micrograph of a fatty liver
Biotech

Cymabay’s NASH drug ambitions dealt serious setback with negative study results

By Adam Feuerstein

TGF Beta
Biotech

Merck to acquire Boston-area immunotherapy startup for up to $770 million

By Kate Sheridan

Jeremy Levin
Biotech

BIO’s new board chair on drug pricing, diversity, and going off-script

By Kate Sheridan

Hans Bishop
Biotech

In a surprise, Hans Bishop takes over as CEO of Grail, the liquid biopsy startup

By Matthew Herper

Play
The Readout LOUD

Listen: The future of cancer treatment, blockbusters interrupted, & an infamous biotech party

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

The Party at BIO
Biotech

Biotech’s infamous party dropped the topless dancers this year. But there were gladiators

By Kate Sheridan

Biotech

Third Rock raises $770 million in new funding round

By Jonathan Saltzman — Boston Globe

IV Drip
Biotech

InflaRx shares fall on failure of lead drug to improve debilitating skin disease

By Adam Feuerstein

Bristol-Myers Squibb
Biotech

Bristol-Myers Squibb shuffles executive lineup after Celgene deal, with R&D chief to depart

By Matthew Herper

ASCO 2019 signage
Biotech

What you missed at ASCO? A lot, as cancer research hastens on

By Adam Feuerstein and Matthew Herper

Lung Cancer Cells - for ASCO
Biotech

At ASCO, targeted lung cancer drugs shrink tumors caused by rare genetic mutations

By Adam Feuerstein

Biotech

Europe approves first gene therapy to treat rare blood disease

By Damian Garde

tennis balls on a blue background
Biotech

Amgen’s drug — targeting an ‘undruggable’ cancer protein — shrank tumors in half of patients

By Adam Feuerstein

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy